Key highlights from Illumina, Inc (ILMN) Q2 2023 Earnings Concall Management Update: [00:07:42] ILMN now expects to ship more than 390 NovaSeq
Illumina, Inc Q2 2023 Earnings Conference Call Insights
Categories
Biotechnology
Ocean Biomedical provides update on programs in malaria, fibrosis, and multiple cancers
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday provided an update on its broad range of programs in malaria, fibrosis, and multiple cancers.
Earnings Summary: Highlights of Illumina’s Q2 2023 results
Biotechnology company Illumina, Inc. (NASDAQ: ILMN) on Wednesday announced financial results for the second quarter of 2023. Second-quarter revenue came in at
Earnings Summary: Highlights of Organon’s Q2 2023 results
Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and earnings for the second quarter of 2023. Second-quarter revenue came
Charles River Laboratories International, Inc Q2 2023 Earnings Conference Call Insights
Key highlights from Charles River Laboratories International, Inc (CRL) Q2 2023 Earnings Concall Q&A Highlights: [00:34:34] Sandy Draper with Guggenheim asked if
Earnings Summary: Charles River Laboratories reports Q2 2023 results
Pharma company Charles River Laboratories International, Inc. (NYSE: CRL) on Wednesday reported financial results for the second quarter of 2023. For the
Ocean Biomedical’s share price target averages $18.21 amid continued progress in research programs
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday shared collective analyst research coverage from three firms, with current Buy recommendations and share price
Earnings Summary: Bio-Techne Corp (TECH) reports higher Q4 profit, revenue
Biotechnology company Bio-Techne Corporation (NASDAQ: TECH) on Tuesday announced financial results for the fourth quarter of 2023, reporting an increase in profit.
Earnings Summary: Zoetis (ZTS) reports fiscal 2023 Q2 results
Animal healthcare company Zoetis Inc. (NYSE: ZTS) announced operating results for the second quarter, reporting higher adjusted profit and sales. Zoetis' June-quarter
AMGN Earnings: Everything you need to know about Amgen’s Q2 results
Amgen Inc. (NASDAQ: AMGN) on Friday reported higher revenues and adjusted earnings for the second quarter of 2023. The biotechnology firm also
CVS Health Corporation Q2 2023 Earnings Conference Call Insights
Key highlights from CVS Health Corporation (CVS) Q2 2023 Earnings Concall Management Update: [00:14:22] CVS said its restructuring efforts are expected to
CVS Health Q2 2023 earnings drop despite higher revenues
Healthcare conglomerate CVS Health Corporation (NYSE: CVS) announced second-quarter 2023 results, reporting lower earnings despite an increase in revenues. June quarter adjusted
Ocean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day
Biopharmaceutical company Ocean Biomedical, Inc. (NASDAQ: OCEA) provided details of its multi-pronged lung cancer program built on novel immunotherapy discoveries by the
BMY Earnings: A snapshot of Bristol-Myers Squibb’s Q2 2023 results
Biotechnology company Bristol Myers Squibb (NYSE: BMY) on Thursday said its second-quarter adjusted earnings decreased year-over-year, hurt by a fall in revenues.
AbbVie (ABBV) Q2 2023 Earnings: Key financials and quarterly highlights
AbbVie (NYSE: ABBV) reported second quarter 2023 earnings results today. Worldwide net revenues were $13.8 billion, down 4.9% on a reported basis,
BIIB Earnings: A snapshot of Biogen’s Q2 2023 financial results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the second quarter of 2023. Total
Infographic: Thermo Fisher Scientific (TMO) Q2 2023 Earnings Results
Thermo Fisher Scientific Inc. (NYSE: TMO) reported second quarter 2023 earnings results today. Revenue declined 3% to $10.69 billion compared to the
Infographic: Highlights of UnitedHealth Group’s (UNH) Q2 2023 earnings
Diversified healthcare company UnitedHealth Group (NYSE: UNH) reported higher earnings and revenues for the second quarter of 2023. The company also raised
Ocean Biomedical focuses its malaria program to address chronic malaria crisis in sub-Saharan Africa
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it is focusing its multi-pronged malaria program to address the chronic malaria
Apogee Therapeutics set to go public. Here’s what you need to know
The US IPO market has remained mostly sluggish so far this year, continuing the weakness experienced in 2022. Meanwhile, there is speculation
Ocean Biomedical (OCEA) joins the Russell 2000 Index
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has been included in the Russell 2000 Index and the broad-market Russell 3000